Answers are grounded in this paper and cite their sources.
Purpose Adjuvant chemotherapy (AC) improves survival in patients with resected stage II–III non-small cell lung cancer (NSCLC); however, its benefits may not be universal. We aimed to identify subgroups in which the benefit of AC may be limited. Methods In this multicenter study, we retrospectively analyzed 1,307 patients with pathological stage II–III NSCLC who underwent complete resection (R0) between 2010 and 2022. Patients were stratified according to the presence of lymphatic (Ly), vascular (V), or pleural (pl) invasion. Overall survival (OS) and cumulative incidence of recurrence (CIR) were compared between the AC and non-AC groups using multivariate Cox regression and Fine–Gray competing-risk models. Results Overall, 775 patients did not receive AC, and 532 did. In the subgroup without Ly, V, or pl invasion (low-risk group), AC did not significantly improve OS (5-year OS: 79.3% vs. 74.3%, P = 0.66) or CIR (5-year CIR: 28.9% vs. 27.6%, P = 0.79). In patients with Ly, V, or pl invasion (high-risk group), AC was associated with better OS (5-year OS: 81.2% vs. 51.2%, P < 0.01) and lower CIR (5-year CIR: 49.9% vs. 52.1%, P = 0.04). Among patients with pathological node-positive disease (pN+), an OS benefit was observed only in the high-risk group. Conclusions In completely resected stage II–III NSCLC, the absence of Ly, V, and pl invasion identified a low-risk subgroup in which the survival benefit of AC appeared limited, particularly in pN0 disease. Pathological invasion status may help identify patients for whom the benefit of AC warrants further evaluation.
No takes yet. Share an insight, caveat, or question.
Hirai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: